GLP-1 Medications for Endometriosis: What the Research Shows, How They Help and How to Access Them in the UK Last reviewed June 26th 2026 Endometriosis affects roughly one in ten women in the UK and remains one of the most underdiagnosed and undertreated conditions in women's health
To calculate the sample size, it was considered a difference of 6 % ( 21 ) in the prevalence of oxidative stress in the groups with and without NAFLD, a power of 80 % and alpha of 5 %
Still, the absolute difference in weight change between tirzepatide and semaglutide in SURMOUNT-5 (6.5% difference at 72 weeks) falls within the confidence interval of Truveta Researchs study (7.5% [5.8% 9.3%] at 52 weeks for ADM versions) for patients without T2D
The former is, I would argue, simply obvious given the facts on the ground of money available with no universal testing regime
Dr Zhou said previous studies had estimated that people with T2DM faced a risk of severe Long COVID symptoms four times higher than that of people without T2DM, although the biological mechanisms behind this increased risk had remained poorly understood
But does it actually work